Biomarkers for Rheumatoid Arthritis disease activity

What are Biomarkers?

Biomarkers are measurable indicators of biological processes, health conditions, or responses to treatments. They can be found in blood, tissues, or other body fluids and include molecules such as proteins, genes, or metabolic byproducts. Biomarkers are essential tools in modern medicine, as they help diagnose diseases, predict risks, monitor treatment effectiveness, and improve our understanding of disease mechanisms. By identifying and studying biomarkers, researchers move closer to more precise and personalised medical approaches.

In the context of rheumatoid arthritis (RA), biomarkers play a key role in assessing disease activity, inflammation, and progression, as well as predicting how patients might respond to therapy.

Why Are Biomarkers Important in Rheumatoid Arthritis?

RA is not just a joint disease but rather a systemic condition that affects the whole body. In RA, the immune system mistakenly attacks the lining of the joints (the synovium), leading to inflammation, swelling, pain, and eventual damage to cartilage and bone. Over time, this can cause severe disability if not managed effectively.

While clinical symptoms such as joint swelling or stiffness can help doctors assess disease activity, they often provide an incomplete picture. That’s where biomarkers come in, as they can detect subtle changes in inflammation, immune system activation, and tissue damage long before symptoms worsen.

Two such biomarkers under investigation are Lipopolysaccharide-Binding Protein (LBP) and Soluble CD14 (sCD14), both of which are related to immune activation caused by bacterial molecules known as lipopolysaccharides (LPS).

Lipopolysaccharide-Binding Protein (LBP)

What Is LBP? Lipopolysaccharide-Binding Protein (LBP) is a protein found in the blood plasma that plays a crucial role in the immune system’s response to bacterial molecules. It binds to lipopolysaccharides (LPS), components of the outer membrane of Gram-negative bacteria, and helps the body recognise and respond to these bacterial signals.

LBP acts as a “carrier” molecule: once it binds to LPS, it transfers it to other receptors such as CD14 and Toll-like receptor 4 (TLR4) on immune cells. This process triggers inflammatory responses aimed at eliminating pathogens. However, when LBP levels remain high, they may signal chronic immune activation, which is common in diseases involving inflammation, like RA.

Why is LBP relevant in RA? Increased levels of LBP in the blood can indicate that bacterial products, such as LPS, are leaking into the bloodstream, a condition known as metabolic endotoxemia. This often results from a weakened gut barrier, sometimes called a “leaky gut.” Research suggests that this leakage can fuel systemic inflammation and potentially worsen autoimmune conditions, including RA. Several studies have shown that patients with RA have higher LBP levels compared to healthy individuals. This suggests that gut-derived inflammation might be an important contributor to RA disease activity.

How is LBP measured? LBP is usually measured in blood serum or plasma using a laboratory method called ELISA (enzyme-linked immunosorbent assay). This test detects the presence and amount of specific proteins. Elevated LBP levels in RA patients can help identify increased inflammatory activity linked to bacterial exposure or gut permeability.

Soluble CD14 (sCD14)

What is sCD14? Soluble CD14 (sCD14) is another key player in the immune response to bacterial components. CD14 is normally found on the surface of certain immune cells, such as monocytes and macrophages, where it acts as a receptor for LPS and other microbial molecules. When inflammation occurs, part of this receptor is released into the bloodstream as soluble CD14.

Why is sCD14 relevant in RA? Like LBP, sCD14 reflects immune system activation and inflammation. Elevated sCD14 levels suggest that the immune system is being chronically stimulated, often due to bacterial byproducts entering the bloodstream or ongoing tissue inflammation. In RA, high sCD14 concentrations are associated with:

• Increased disease activity and severity
• Activation of macrophages and fibroblast-like synovial cells, which drive joint inflammation
• Enhanced production of inflammatory cytokines

How is sCD14 measured? sCD14 levels can be measured in blood plasma or serum, again typically through ELISA-based methods. Tracking sCD14 levels alongside LBP may provide a more complete picture of RA-related inflammation, particularly in connection with bacterial translocation and systemic immune activation.

How do LBP and sCD14 Work Together?

LBP and sCD14 are part of the same immune recognition pathway, the LPS–LBP–CD14–TLR4 axis. This system allows the body to detect bacterial endotoxins and mount an immune response. In a healthy state, this response is short-lived and helps fight infection. However, in chronic inflammatory diseases, like RA, this pathway may remain constantly activated, contributing to persistent inflammation and joint damage.

When LPS from the gut enters the bloodstream, LBP binds to it and delivers it to CD14 and TLR4 on immune cells. This triggers a chain reaction, leading to the release of inflammatory mediators such as TNF-α, IL-1β, and IL-6, which are all well-known drivers of RA pathology.

Thus, monitoring both LBP and sCD14 can provide valuable insights into the inflammatory status of RA patients, helping to:

• Assess disease activity more precisely
• Identify patients at risk of flare-ups
• Evaluate response to therapy, especially treatments targeting inflammation or gut health

The Role of LBP and sCD14 in the ENDOTARGET Project

The ENDOTARGET project aims to unravel the links between the gut–joint axis and rheumatic diseases such as rheumatoid arthritis, osteoarthritis, and spondyloarthritis. Researchers are investigating how bacterial products from the gut may influence systemic inflammation and joint health.

By analysing these biomarkers in patient cohorts and comparing them to healthy controls, the project seeks to better understand how the gut microbiome and intestinal permeability contribute to RA pathogenesis. This could eventually lead to new diagnostic tools and targeted interventions.

 

Glossary

Autoimmune Disease: A condition in which the immune system mistakenly attacks the body’s own tissues.

Biomarker: A measurable biological indicator used to detect or monitor a disease or condition.

Cytokines: Small proteins released by immune cells that regulate inflammation and immune responses.

Endotoxemia: The presence of bacterial toxins (like LPS) in the bloodstream.

Enzyme-Linked Immunosorbent Assay (ELISA): A laboratory method used to measure the concentration of specific proteins in a sample.

Gram-Negative Bacteria: A type of bacteria with an outer membrane containing lipopolysaccharides (LPS), which can trigger immune responses.

Lipopolysaccharides (LPS): Molecules found on the surface of Gram-negative bacteria that can cause inflammation when entering the bloodstream.

Lipopolysaccharide-Binding Protein (LBP): A plasma protein that binds to bacterial lipopolysaccharides and activates immune responses.

Macrophages: Immune cells that engulf and digest pathogens and cellular debris.

Metabolic Endotoxemia: A mild, chronic form of endotoxemia caused by increased gut permeability, linked to systemic inflammation.

Monocytes: A type of white blood cell that can develop into macrophages and help regulate immune responses.

Rheumatoid Arthritis (RA): A chronic autoimmune disease causing inflammation, pain, and progressive damage in the joints.

Soluble CD14 (sCD14): A circulating immune receptor protein released during inflammation, acting as a marker of immune activation.

Toll-Like Receptor 4 (TLR4): A receptor on immune cells that detects bacterial molecules like LPS and triggers inflammation.

Tumor Necrosis Factor Alpha (TNF-α): A pro-inflammatory cytokine involved in systemic inflammation and autoimmune diseases.

References

Wen W, Li Y, Cheng Y, He J, Jia R, Li C, et al. Lipopolysaccharide-binding protein is a sensitive disease activity biomarker for rheumatoid arthritis. Clin Exp Rheumatol. 2018;36(2):233–40. 45.

Ichise Y, Saegusa J, Tanaka-Natsui S, Naka I, Hayashi S, Kuroda R, et al. Solu‑ ble CD14 Induces Pro-inflammatory Cytokines in Rheumatoid Arthritis Fibroblast-Like Synovial Cells via Toll-Like Receptor 4. Cells. 2020;9(7):1689. 46.

Koh JH, Lee S, Kim HS, Lee K, Lee CS, Yoo SA, et al. Development of monitoring system for assessing rheumatoid arthritis within 5 minutes using a drop of bio-fluids. J Clin Med. 2020;9(11):1–17.